Clinical Trials
10 trialsNCT05619367 2025-12-23
A Compassionate Use (CU) Program of Odronextamab
Regeneron Pharmaceuticals
Available
NCT01833039 2025-02-03
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Janssen Biotech, Inc.
Approved for marketing
NCT04052854 2024-10-23
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
BeiGene
No longer available
NCT03153462 2023-11-08
ZUMA-9
Gilead Sciences
Approved for marketing
NCT05131438 2023-03-27
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
EQRx International, Inc.
No longer available
NCT04162756 2021-10-14
ZUMA-18
Gilead Sciences
Approved for marketing
NCT04705454 2021-05-12
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
No longer available
NCT02715843 2019-10-11
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Molecular Templates, Inc.
No longer available
NCT02437019 2017-03-20
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Janssen-Cilag Farmaceutica Ltda.
Approved for marketing
NCT00423826 2016-02-29
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Barbara Ann Karmanos Cancer Institute
No longer available